ARTICLE | Clinical News

CNP520: Phase II started

September 12, 2016 7:00 AM UTC

Novartis and Amgen began the double-blind, placebo-controlled, international Phase II Alzheimer’s Prevention Initiative (API) Generation Study to evaluate intramuscular CAD106 at weeks 1, 7 and 13 and quarterly thereafter or once-daily oral CNP520 for >=5 years. The trial will enroll about 1,340 cognitively healthy volunteers ages 60-75 at a high risk for AD due to having 2 copies of the E4 allele of the apolipoprotein E (APOE) gene. ...